Results 91 to 100 of about 7,490 (132)

Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiation [PDF]

, 2016
Jakub Neradil, Jaroslav Sterba, Martin Sramek, Renata Veselska   +3 more
core   +1 more source

Rapid Onset Liver Injury Due to Azacitidine Through Possibly a Unique Mechanism of Hypoperfusion of the Liver. [PDF]

J Investig Med High Impact Case Rep
Hatipoglu D, Jamali A, Sheng E, Reddy KR.   +3 more
europepmc   +1 more source

Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy. [PDF]

Med Sci (Basel)
Baraka B, Mathiyalagan N, Al-Ani M, Mohindru G, Semple T, Divyateja H, Figueredo G, Quinlan P, Aithal GP, Madhusudan S.   +9 more
europepmc   +1 more source

From Plasma Kinetics to Cellular Pharmacology [PDF]

, 1996
Pinedo, H.M.
core   +1 more source

Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system. [PDF]

Front Immunol
Liu W, Song X, Du Q, Liu J.
europepmc   +1 more source

The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research. [PDF]

Int J Mol Sci
Grigoreva TA, Kindt DN, Sagaidak AV, Romanova AA, Tribulovich VG.   +4 more
europepmc   +1 more source

The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies. [PDF]

Glob Heart
Fan G, Zuo H, Lin L, Xu C, Yan R.
europepmc   +1 more source

The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy. [PDF]

BMC Cancer
Wang YL, Chang TY, Chen SH, Hsiao YW, Wen YC, Jaing TH.   +5 more
europepmc   +1 more source

Pharmacovigilance insights into drug-associated venous thromboembolism. [PDF]

Int J Surg
Cai X, Chen G, Wang H, Wang L, Hu C.
europepmc   +1 more source

Influence of xanthine oxidase and inosine monophosphate dehydrogenase polymorphisms on 6-mercaptopurine treatment response in pediatric acute lymphoblastic leukemia. [PDF]

Sci Rep
Sabirova Z, Boucetta MTE, Bensouyad RR, Gagné V, Théorêt Y, Nava T, Leclerc JM, Laverdière C, Sinnett D, Tran TH, Krajinovic M.   +10 more
europepmc   +1 more source